These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: AG-4 complement-fixing antibodies in cervical cancer and herpes-infected patients using local herpes simplex virus type 2.
    Author: Arsenakis M, Georgiou GM, Welsh JK, Cauchi MN, May JT.
    Journal: Int J Cancer; 1980 Jan 15; 25(1):67-71. PubMed ID: 6249764.
    Abstract:
    The incidence of anti-AG-4 complement-fixing antibodies in Australian cervical carcinoma (CaCx), herpes simplex virus (HSV) type 1 and 2, and control patients, was investigated using local HSV strains. The local HSV strains (both HSV-IMI and HSV-2MI) were found, by neutralization experiments, to vary from the American prototype strains. All HSV-2-strains tested were able to induce AG-4 in 4-h infected HEp-2 cells. Anti-AG-4-complement-fixing antibodies were detected in 40% of dysplasia patients, 60% of carcinoma-in-situ patients, 75% of CaCx patients, 65% of CaCx post-operative patients, 88% of HSV-2 patients with active lesions, 10% of HSV-1 patients with active lesions, 10--20% of normal patients and 20% of patients with cancer, other than CaCx. The AG-4 test is tumour-specific in that it distinguishes CaCx from other cancer patients tested, but it cannot distinguish HSV-2 patients from CaCx patients.
    [Abstract] [Full Text] [Related] [New Search]